

Mats Jerkeman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9340541/publications.pdf>

Version: 2024-02-01

211
papers

6,970
citations

71102

41
h-index

69250

77
g-index

215
all docs

215
docs citations

215
times ranked

6303
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials. <i>Leukemia</i> , 2022, 36, 177-188.	7.2	11
2	Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial. <i>British Journal of Haematology</i> , 2022, 196, 437-440.	2.5	5
3	Advances in immune therapies in hematological malignancies. <i>Journal of Internal Medicine</i> , 2022, 292, 205-220.	6.0	5
4	Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience. <i>Hematological Oncology</i> , 2022, 40, 23-31.	1.7	1
5	High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis. <i>Blood</i> , 2022, 139, 1557-1563.	1.4	20
6	Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 655-666.	2.8	1
7	Molecular features encoded in the ctDNA reveal heterogeneity and predict outcome in high-risk aggressive B-cell lymphoma. <i>Blood</i> , 2022, 139, 1863-1877.	1.4	43
8	Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen – a real world study on patients diagnosed in Sweden 2007-2017. <i>Haematologica</i> , 2022, 107, 740-743.	3.5	9
9	Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line – A population-based study of 736 patients. <i>British Journal of Haematology</i> , 2022, 198, 267-277.	2.5	16
10	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	2.7	1
11	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 2482-2494.	27.0	83
12	Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA7502-LBA7502.	1.6	6
13	Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 298-308.	1.2	127
14	The DLBCL90 gene expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma. <i>EJHaem</i> , 2021, 2, 107-111.	1.0	1
15	Association between anthropometry and lifestyle factors and risk of B-cell lymphoma: An exposome-wide analysis. <i>International Journal of Cancer</i> , 2021, 148, 2115-2128.	5.1	9
16	Detecting deviations from the efficacy and safety results of single-arm trials using real-world data: The case of a CAR-T cell therapy in B-cell lymphoma. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 514-519.	1.9	3
17	EHA/ESMO Clinical Practice Guidelines for the Management of Malignant Lymphoma: Recommendations for the Second Phase of the COVID-19 Pandemic. <i>HemaSphere</i> , 2021, 5, e529.	2.7	11
18	Incidence of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) including CNS relapse in a population-based cohort of 4243 patients in Sweden. <i>Blood Cancer Journal</i> , 2021, 11, 9.	6.2	32

#	ARTICLE	IF	CITATIONS
19	Clinical Characteristics and Histopathological Patterns of Hodgkin Lymphoma and Treatment Outcomes at a Tertiary Cancer Center in Ethiopia. <i>JCO Global Oncology</i> , 2021, 7, 277-288.	1.8	5
20	Infiltration of CD163 ⁺ , PD-L1 ⁺ and FoxP3 ⁺ positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. <i>British Journal of Haematology</i> , 2021, 193, 520-531.	2.5	12
21	Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival. <i>Blood Advances</i> , 2021, 5, 1638-1647.	5.2	8
22	How should we use ibrutinib in patients with mantle cell lymphoma?. <i>British Journal of Haematology</i> , 2021, 193, 445-446.	2.5	0
23	Myocardial infarction in diffuse large B-cell lymphoma patients – a population-based matched cohort study. <i>Journal of Internal Medicine</i> , 2021, 290, 1048-1060.	6.0	10
24	Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets. <i>Leukemia and Lymphoma</i> , 2021, 62, 2637-2647.	1.3	2
25	Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma. <i>Cancer Reports</i> , 2021, , e1524.	1.4	1
26	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	2.4	21
27	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	1.2	7
28	Impact of comorbidity in elderly patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients. <i>Blood Advances</i> , 2021, , .	5.2	2
29	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. <i>HemaSphere</i> , 2021, 5, e510.	2.7	18
30	Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition. <i>European Journal of Nutrition</i> , 2020, 59, 813-823.	3.9	8
31	<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , 2020, 105, 1604-1612.	3.5	96
32	Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study. <i>British Journal of Haematology</i> , 2020, 189, 106-116.	2.5	13
33	An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement. <i>Cancer Medicine</i> , 2020, 9, 663-670.	2.8	17
34	National e-library for standardized chemotherapy regimens. <i>Acta Oncologica</i> , 2020, 59, 1079-1083.	1.8	3
35	p53 is associated with high-risk and pinpoints <i>TP53</i> missense mutations in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 796-805.	2.5	31
36	Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk. <i>BMC Cancer</i> , 2020, 20, 1202.	2.6	3

#	ARTICLE	IF	CITATIONS
37	Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL. <i>Blood</i> , 2020, 135, 2000-2004.	1.4	26
38	Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis. <i>Blood Advances</i> , 2020, 4, 1906-1915.	5.2	35
39	Outcome and determinants of failure to complete primary <sc>Râ€CHOP</sc> treatment for reasons other than nonâ€response among patients with diffuse large Bâ€cell lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 740-748.	4.1	10
40	Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study. <i>International Journal of Cancer</i> , 2020, 147, 1649-1656.	5.1	4
41	Trends in the prevalence, incidence and survival of nonâ€Hodgkin lymphoma subtypes during the 21st century â€ a Swedish lymphoma register study. <i>British Journal of Haematology</i> , 2020, 189, 1083-1092.	2.5	24
42	Mantle Cell Lymphoma of Mucosaâ€Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. <i>HemaSphere</i> , 2020, 4, e302.	2.7	10
43	Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women. <i>Anticancer Research</i> , 2020, 40, 1513-1517.	1.1	1
44	Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. <i>Blood</i> , 2020, 136, 36-36.	1.4	5
45	Idelalisib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: First Results from the Nordic Lymphoma Group NLG-LBC-07 (ILIAD) Phase II Trial. <i>Blood</i> , 2020, 136, 33-33.	1.4	1
46	Evaluation of Eligibility for CAR-T Cell Therapy in a Population-Based Cohort of 3550 Patients with Incident Diffuse Large B-Cell Lymphoma (DLBCL) in Sweden. <i>Blood</i> , 2020, 136, 38-39.	1.4	1
47	Pre-Treatment Health-Related Quality of Life Parameters May Have Prognostic Impact in Elderly Patients with Mantle Cell Lymphoma. the Nordic Lymphoma Group MCL4 (LENA-BERIT) Experience. <i>Blood</i> , 2020, 136, 8-9.	1.4	0
48	Establishment of an In Vivo Mouse Model to Study and Overcome Infusion Related Reactions Associated with Fcgr1b Antibody Administration. <i>Blood</i> , 2020, 136, 4-5.	1.4	0
49	Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - Data from the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase I Trial: Stopping Treatment in Molecular Remission Is Feasible. <i>Blood</i> , 2020, 136, 15-15.	1.4	7
50	Unraveling Actionable Target Mutations in Formalin Fixed Tissue in Mantle Cell Lymphoma. <i>Blood</i> , 2020, 136, 25-26.	1.4	0
51	Impact of Comorbidities on Outcomes of Peripheral T Cell Lymphoma in Elderly Patients: An International Retrospective Study. <i>Blood</i> , 2020, 136, 27-28.	1.4	0
52	17-BI-1206-02 Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to Fcgr1b, in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or Is Refractory to Rituximab. <i>Blood</i> , 2020, 136, 36-37.	1.4	1
53	Nationwide Investigation of Patient Trajectories in Mantle Cell Lymphoma - Initial Data from the Swedish MCL C<i>complete</i> Project. <i>Blood</i> , 2020, 136, 3-4.	1.4	0
54	Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide. <i>Experimental Hematology and Oncology</i> , 2019, 8, 16.	5.0	13

#	ARTICLE	IF	CITATIONS
55	THE IMMUNE MICROENVIRONMENT AS A PROGNOSTIC TOOL FOR MCL PATIENTS. <i>Hematological Oncology</i> , 2019, 37, 344-345.	1.7	0
56	Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs. <i>Oncologist</i> , 2019, 24, e1236-e1250.	3.7	36
57	Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases. <i>Pharmaceutical Medicine</i> , 2019, 33, 83-88.	1.9	2
58	PHASE 1/2A CLINICAL TRIALS OF BI-1206, A MONOCLONAL ANTIBODY TO FCÎ“RIIB, ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH RITUXIMAB IN SUBJECTS WITH B-CELL MALIGNANCIES. <i>Hematological Oncology</i> , 2019, 37, 520-521.	1.7	0
59	EARLY PROGRESSION OF MANTLE CELL LYMPHOMA DEPICTS A HIGH-RISK DISEASE WITH POOR RESPONSE TO SUBSEQUENT THERAPIES AND A DISMAL OUTCOME. <i>Hematological Oncology</i> , 2019, 37, 242-242.	1.7	0
60	SERUM BIOMARKERS ARE ASSOCIATED WITH TREATMENT RESPONSE IN RELAPSED MANTLE CELL LYMPHOMA. <i>Hematological Oncology</i> , 2019, 37, 403-403.	1.7	0
61	Is there a role for immunomodulatory drugs in the treatment of mantle cell lymphoma?. <i>Annals of Lymphoma</i> , 2019, 3, 2-2.	4.5	1
62	EVOLUTION OF CLONAL HEMATOPOIESIS IN MANTLE CELL LYMPHOMA PATIENTS BEFORE, DURING, AND AFTER INDUCTION CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION. <i>Hematological Oncology</i> , 2019, 37, 239-240.	1.7	0
63	YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA INCLUDING BCL-2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE-DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS. <i>Hematological Oncology</i> , 2019, 37, 132-132.	1.7	0
64	Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition. <i>American Journal of Epidemiology</i> , 2019, 188, 274-281.	3.4	6
65	Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large Bâ€cell lymphoma: a Swedish lymphoma register study. <i>Journal of Internal Medicine</i> , 2019, 285, 455-468.	6.0	27
66	Treatment Intensity, Timing of Relapse and Outcome of 713 Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Setting in Sweden. <i>Blood</i> , 2019, 134, 4111-4111.	1.4	3
67	A Circular RNA Molecule, circRAB11FIP1, Is Associated with TP53 Mutations and Is of Potential Prognostic and Functional Significance in Mantle Cell Lymphoma: Data from the Nordic MCL2 and MCL3 Studies. <i>Blood</i> , 2019, 134, 1495-1495.	1.4	1
68	Triangle: Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a Randomized European MCL Network Trial. <i>Blood</i> , 2019, 134, 2816-2816.	1.4	14
69	Incidence of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Including CNS Relapse in a Population-Based Cohort of 4205 Patients in Sweden. <i>Blood</i> , 2019, 134, 399-399.	1.4	0
70	Autologous Stem Cell Transplantation in Mantle Cell Lymphoma - Selection Mechanisms and Survival By Age Group. <i>Blood</i> , 2019, 134, 4572-4572.	1.4	0
71	Genomic Profiling of Circulating Tumor DNA Reveals Patterns of Response and Refractoriness in Aggressive B-Cell Lymphoma - a Nordic Lymphoma Group Correlative Study. <i>Blood</i> , 2019, 134, 1481-1481.	1.4	1
72	The DLBCL90 Double-Hit Gene Expression Signature Is Not Associated with Inferior Survival in Young High-Risk Patients with Diffuse Large B-Cell Lymphoma Treated with Dose-Intensive Immunochemotherapy. <i>Blood</i> , 2019, 134, 1485-1485.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. <i>Leukemia</i> , 2018, 32, 1799-1803.	7.2	67
74	Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e109-e116.	4.6	117
75	Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study. <i>Hematological Oncology</i> , 2018, 36, 159-165.	1.7	10
76	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 583-586.	2.5	49
77	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. <i>Leukemia and Lymphoma</i> , 2018, 59, 1814-1828.	1.3	23
78	Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IP1, IPI, and NCCN-IP1. <i>Cancer Medicine</i> , 2018, 7, 114-122.	2.8	28
79	Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-13.	2.1	27
80	A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia. <i>Npj Precision Oncology</i> , 2018, 2, 18.	5.4	14
81	Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of follow-up. <i>PLoS ONE</i> , 2018, 13, e0202651.	2.5	11
82	Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID). <i>Blood Advances</i> , 2018, 2, 1386-1392.	5.2	22
83	Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 1020-1028.	4.1	23
84	Six cycles of R-CHOP-21 are not inferior to eight cycles for treatment of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Population-based Study. <i>Annals of Oncology</i> , 2018, 29, 1882-1883.	1.2	10
85	Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma. <i>Haematologica</i> , 2018, 103, e541-e543.	3.5	19
86	Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF- κ B activity. <i>BMC Cancer</i> , 2018, 18, 466.	2.6	4
87	Incidence and Outcome of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in a Population-Based Cohort of 3165 Patients in Sweden. <i>Blood</i> , 2018, 132, 2975-2975.	1.4	1
88	Relapse Risk and Loss in Expectation of Lifetime in Young Classical Hodgkin Lymphoma Patients - a Nordic Lymphoma Group Study of 2,582 Patients. <i>Blood</i> , 2018, 132, 930-930.	1.4	1
89	Prognostic Implications of Specific Comorbidities in Mantle Cell Lymphoma Patients, a Swedish Lymphoma Registry Study. <i>Blood</i> , 2018, 132, 2891-2891.	1.4	0
90	SAMHD1 Is Variably Expressed in Mantle Cell Lymphoma and Correlated to SOX11 but Not to Survival. <i>Blood</i> , 2018, 132, 4136-4136.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Outcome and Determinants of Failure to Complete 6-8 Cycles of Primary R-CHOP Treatment for Reasons Unrelated to Progression Among Patients with Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2018, 132, 4200-4200.	1.4	0
92	Clinical Characteristics and Outcomes Among Very Elderly Patients with Major Lymphoma Subtypes: A Nordic Lymphoma Group Study. <i>Blood</i> , 2018, 132, 571-571.	1.4	0
93	Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. <i>Hematological Oncology</i> , 2017, 35, 151-157.	1.7	12
94	The addition of etoposide to <sc>CHOP</sc> is associated with improved outcome in <sc>ALK</sc>+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study. <i>British Journal of Haematology</i> , 2017, 178, 739-746.	2.5	28
95	Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. <i>Leukemia and Lymphoma</i> , 2017, 58, 2824-2832.	1.3	15
96	Targeting of B-cell receptor signalling in B-cell malignancies. <i>Journal of Internal Medicine</i> , 2017, 282, 415-428.	6.0	37
97	Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2815-2823.	1.3	19
98	Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and Tj ETQq0 0 0 r BT /Overlock 10 Tf 428-435.	2.0	56
99	TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. <i>Blood</i> , 2017, 130, 1903-1910.	1.4	296
100	IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY. <i>Hematological Oncology</i> , 2017, 35, 143-144.	1.7	4
101	DOSE-DENSE CHEMOIMMUNOTHERAPY AND CNS PROPHYLAXIS IN PATIENTS WITH HIGH-RISK DLBCL: A COMPARISON OF NORDIC CRY-04 AND CHIC STUDIES. <i>Hematological Oncology</i> , 2017, 35, 199-200.	1.7	0
102	MANTLE CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE: A RETROSPECTIVE MULTICENTER OBSERVATIONAL STUDY OF THE EUROPEAN MANTLE CELL LYMPHOMA NETWORK. <i>Hematological Oncology</i> , 2017, 35, 202-203.	1.7	0
103	BORTEZOMIB PREVENTS DEVELOPMENT OF CYTARABINE RESISTANCE IN A MANTLE CELL LYMPHOMA <i>IN VITRO</i> MODEL. <i>Hematological Oncology</i> , 2017, 35, 400-401.	1.7	0
104	Frequency and clinical implications of SOX11 expression in Burkitt lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 1760-1763.	1.3	4
105	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv62-iv71.	1.2	387
106	Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma. <i>Blood Advances</i> , 2017, 1, 2257-2268.	5.2	25
107	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 4019-4026.	1.6	50
108	No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. <i>British Journal of Haematology</i> , 2016, 173, 236-244.	2.5	28

#	ARTICLE	IF	CITATIONS
109	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , 2016, 91, 894-899.	4.1	15
110	Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. <i>Blood</i> , 2016, 128, 1814-1820.	1.4	75
111	15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (<scp>MCL</scp>2): prolonged remissions without survival plateau. <i>British Journal of Haematology</i> , 2016, 175, 410-418.	2.5	170
112	Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. <i>British Journal of Haematology</i> , 2016, 175, 614-622.	2.5	14
113	Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study. <i>Blood Cancer Journal</i> , 2016, 6, e501-e501.	6.2	5
114	Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan—two case studies. <i>European Journal of Haematology</i> , 2016, 96, 541-543.	2.2	5
115	Season of diagnosis is associated with overall survival in patients with diffuse large B-cell lymphoma but not with Hodgkin's lymphoma—A population-based Swedish Lymphoma Register study. <i>European Journal of Haematology</i> , 2016, 97, 393-398.	2.2	2
116	Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2016, 387, 770-778.	13.7	389
117	Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. <i>Leukemia</i> , 2016, 30, 1428-1430.	7.2	19
118	Targeted Sequencing of Diagnostic Samples Correlated to Clinical Outcome: Data from the Nordic Mantle Cell Lymphoma (MCL2 and MCL3) Studies with Long-Term Follow-up. <i>Blood</i> , 2016, 128, 1095-1095.	1.4	4
119	Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years. <i>Blood</i> , 2016, 128, 146-146.	1.4	4
120	Ibrutinib-Lenalidomide-Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma: First Results from the Nordic Lymphoma Group MCL6 (PHILEMON) Phase II Trial. <i>Blood</i> , 2016, 128, 148-148.	1.4	12
121	Resistance to Cytarabine in Mantle Cell Lymphoma Is Mediated By Down-Regulation of Deoxycytidine Kinase at the Protein Level. <i>Blood</i> , 2016, 128, 1769-1769.	1.4	1
122	An International Assessment of Event-Free Survival at 24 Months (EFS24) and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2016, 128, 920-920.	1.4	0
123	Dose-Dense Chemoimmunotherapy Including Early CNS Prophylaxis for High-Risk DLBCL. -Final Analysis from a Nordic Phase II Study (the CHIC trial). <i>Blood</i> , 2016, 128, 1854-1854.	1.4	2
124	miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. <i>Blood</i> , 2015, 125, 2669-2677.	1.4	44
125	Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study. <i>Blood</i> , 2015, 126, 36-41.	1.4	44
126	Pharmacologically relevant doses of valproate upregulate CD20 expression in three diffuse large B-cell lymphoma patients in vivo. <i>Experimental Hematology and Oncology</i> , 2015, 4, 4.	5.0	18

#	ARTICLE	IF	CITATIONS
127	Long-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009: trends in cure proportions by clinical characteristics. <i>American Journal of Hematology</i> , 2015, 90, 1128-1134.	4.1	36
128	The impact of age on survival of diffuse large B-cell lymphoma - a population-based study. <i>Acta Oncologica</i> , 2015, 54, 916-923.	1.8	20
129	Sick leave and disability pension in Hodgkin lymphoma survivors by stage, treatment, and follow-up time - a population-based comparative study. <i>Journal of Cancer Survivorship</i> , 2015, 9, 599-609.	2.9	35
130	Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study. <i>Acta Oncologica</i> , 2015, 54, 924-932.	1.8	19
131	Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo. <i>Cancer Cell</i> , 2015, 27, 473-488.	16.8	108
132	Sick leave and disability pension among Swedish testicular cancer survivors according to clinical stage and treatment. <i>Acta Oncologica</i> , 2015, 54, 1770-1780.	1.8	17
133	Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 3993-3998.	1.6	74
134	Addition of Etoposide to CHOP Is Associated with Improved Outcome in Adult Anaplastic Large Cell Lymphoma Patients: A Nordic Lymphoma Group Study. <i>Blood</i> , 2015, 126, 340-340.	1.4	1
135	Ibrutinib Vs Tamsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2015, 126, 469-469.	1.4	3
136	Low RBM3 Protein Expression Correlates with Clinical Stage, Prognostic Classification and Increased Risk of Treatment Failure in Testicular Non-Seminomatous Germ Cell Cancer. <i>PLoS ONE</i> , 2015, 10, e0121300.	2.5	21
137	Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration. <i>Blood</i> , 2015, 126, 3865-3865.	1.4	0
138	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 1501-1501.	1.4	0
139	Frequency and Clinical Implication of SOX11 Expression in Burkitt Lymphoma. <i>Blood</i> , 2015, 126, 5039-5039.	1.4	0
140	Valproate in Combination with Rituximab and CHOP As First Line Therapy in Diffuse Large B-Cell Lymphoma (VALFRID): Preliminary Results from a Phase I Trial with a Dose Expansion Cohort. <i>Blood</i> , 2015, 126, 3939-3939.	1.4	0
141	Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Tamsirolimus. <i>Blood</i> , 2015, 126, 1542-1542.	1.4	0
142	Improvement in survival of diffuse large B-cell lymphoma in relation to age, gender, International Prognostic Index and extranodal presentation: a population based Swedish Lymphoma Registry study. <i>Leukemia and Lymphoma</i> , 2014, 55, 1838-1843.	1.3	16
143	SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma - a Nordic Lymphoma Group study. <i>British Journal of Haematology</i> , 2014, 166, 98-108.	2.5	110
144	Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry. <i>Acta Oncologica</i> , 2014, 53, 927-934.	1.8	28

#	ARTICLE	IF	CITATIONS
145	High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group Mantle Cell Lymphoma 5 trial. <i>Leukemia and Lymphoma</i> , 2014, 55, 1206-1208.	1.3	18
146	Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays. <i>Leukemia Research</i> , 2014, 38, 682-690.	0.8	14
147	Deregulation of COMMD1 Is Associated with Poor Prognosis in Diffuse Large B-cell Lymphoma. <i>PLoS ONE</i> , 2014, 9, e91031.	2.5	19
148	Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. <i>Blood</i> , 2014, 124, 1288-1295.	1.4	113
149	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. <i>Blood</i> , 2014, 123, 2953-2959.	1.4	90
150	Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. <i>Blood</i> , 2014, 124, 1570-1577.	1.4	309
151	Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8529-8529.	1.6	5
152	Patterns of Central Nervous System Relapse in Peripheral T-Cell Lymphomas â€“ Population-Based Data from the Swedish Lymphoma Registry. <i>Blood</i> , 2014, 124, 1632-1632.	1.4	1
153	Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials. <i>Blood</i> , 2014, 124, 2994-2994.	1.4	0
154	Plasma Affinity Proteomic Immunoprofiling As a Novel Prognostic Tool in High Risk Diffuse Large B-Cell Lymphoma Patients: A Nordic Lymphoma Group Study. <i>Blood</i> , 2014, 124, 1618-1618.	1.4	0
155	The Prognostic Impact of Comorbidity in Peripheral T-Cell Lymphomas: a Swedish Lymphoma Registry Study. <i>Blood</i> , 2014, 124, 1635-1635.	1.4	0
156	R-CHOEP-14 Is Associated with Superior Overall Survival Compared to R-CHOP-21 and R-CHOP-14 in Patients with DLBCL â‰¥70 Years â€“ a Swedish Lymphoma Registry Population Based Study. <i>Blood</i> , 2014, 124, 4427-4427.	1.4	0
157	Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. <i>Annals of Oncology</i> , 2013, 24, 1879-1886.	1.2	65
158	Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. <i>Annals of Oncology</i> , 2013, 24, 1385-1392.	1.2	99
159	Role Of High-Dose Cytarabine and Total Body Irradiation Conditioning before Autologous Stem Cell Transplantation In Mantle Cell Lymphoma - A Comparison Of Nordic MCL2, HOVON 45, and European MCL Younger Trials. <i>Blood</i> , 2013, 122, 3367-3367.	1.4	6
160	Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy For Patients >65 Years With Mantle Cell Lymphoma: Preliminary Results From The Nordic Lymphoma Group MCL4 (LENA-BERIT) Phase I-II Trial. <i>Blood</i> , 2013, 122, 4377-4377.	1.4	11
161	Dose-Dense Chemoimmunotherapy and Early Central Nervous System Prophylaxis For High-Risk Diffuse Large B-Cell Lymphoma. â€“Preliminary Results From a Nordic Phase II Study. <i>Blood</i> , 2013, 122, 849-849.	1.4	2
162	Real World Data On Primary Treatment For Mantle Cell Lymphoma 2000-2011 â€“ a Nordic Lymphoma Group Observational Study. <i>Blood</i> , 2013, 122, 4358-4358.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Increased Expression Levels Of SOX11 Correlates To Overall Survival and Adds Prognostic Value To The MIPI and MIPI-B Index In a Homogenously Treated Cohort. <i>Blood</i> , 2013, 122, 4272-4272.	1.4	0
164	Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem-cell support: still very long survival but. <i>British Journal of Haematology</i> , 2012, 158, 815-816.	2.5	1
165	High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapy. <i>European Journal of Haematology</i> , 2012, 89, 395-402.	2.2	11
166	Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem-cell support: still very long survival but late relapses do occur. <i>British Journal of Haematology</i> , 2012, 158, 355-362.	2.5	241
167	Use of exon-based transcriptome profiling to identify novel signaling pathways and survival-associated genes in diffuse large B-cell lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 8074-8074.	1.6	0
168	Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy*. <i>European Journal of Haematology</i> , 2011, 86, 124-128.	2.2	80
169	Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines. <i>Experimental Cell Research</i> , 2011, 317, 1179-1191.	2.6	15
170	Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. <i>Leukemia and Lymphoma</i> , 2011, 52, 2090-2096.	1.3	24
171	Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. <i>Leukemia and Lymphoma</i> , 2011, 52, 1929-1935.	1.3	42
172	Lenalidomide, Bendamustine, and Rituximab As First-Line Therapy for Patients > 65 Years with Mantle Cell Lymphoma: Results From the Phase I Portion of the Nordic Lymphoma Group MCL4 (LENA-BERIT) Trial. <i>Blood</i> , 2011, 118, 2700-2700.	1.4	12
173	The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). <i>Blood</i> , 2010, 115, 1530-1533.	1.4	167
174	Phase II trial of zanolimumab (HuMaxCD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. <i>British Journal of Haematology</i> , 2010, 150, 565-573.	2.5	73
175	Prognostic impact of protein kinase C β II expression in R-CHOP-treated diffuse large B-cell lymphoma patients. <i>Modern Pathology</i> , 2010, 23, 686-693.	5.5	20
176	R-CHOEP-14 + 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score \geq 3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years. <i>Blood</i> , 2010, 116, 2805-2805.	1.4	2
177	Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem Cell Transplantation in Mantle Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 4365-4370.	1.6	123
178	Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas. <i>European Journal of Haematology</i> , 2009, 82, 364-372.	2.2	31
179	Identification of molecular targets associated with transformed diffuse large B cell lymphoma using highly purified tumor cells. <i>American Journal of Hematology</i> , 2009, 84, 803-808.	4.1	41
180	Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Modern Pathology</i> , 2009, 22, 1094-1101.	5.5	97

#	ARTICLE	IF	CITATIONS
181	90y-Ibritumumab Tiuxetan (Zevalin [®])-BEAM/C with Autologous Stem Cell Support as Frontline Therapy for Advanced Mantle Cell Lymphoma. "Preliminary Results From the Third Nordic MCL Phase II Study (MCL3)". Blood, 2009, 114, 932-932.	1.4	4
182	Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma. British Journal of Haematology, 2008, 141, 423-432.	2.5	35
183	B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Letters, 2008, 259, 138-145.	7.2	22
184	Nuclear expression of the non-B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood, 2008, 111, 800-805.	1.4	185
185	Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo "purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 2008, 112, 2687-2693.	1.4	571
186	Epidemiology and 15-Year Follow up after Cladribine Treatment of Patients with Hairy Cell Leukemia (HCL): Population-Based Swedish Data and Long-Term Follow-up of Scandinavian Study Patients Identify Older Patients with Poorer Outcome. Blood, 2008, 112, 4166-4166.	1.4	0
187	Simvastatin Sensitizes Bcl-2-Negative DLBCL Cell Lines to CHOP: A Finding with Possible Clinical Implications for Treatment of Bcl-2-Negative DLBCL?. Blood, 2008, 112, 5044-5044.	1.4	0
188	R-CHOEP-14 X 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma (DLBCL)/Follicular Lymphoma (FL) Grade 3 with Age Adjusted IPI Score 2-3: Preliminary Results of a Nordic Lymphoma Group (NLG) Phase 2 Study Including 160 Patients Aged 18- 64 Years. Blood, 2008, 112, 3604-3604.	1.4	0
189	CD40 expression identifies a prognostically favourable subgroup of diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2007, 48, 1774-1779.	1.3	21
190	Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC- ζ II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leukemia and Lymphoma, 2007, 48, 2221-2232.	1.3	52
191	Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma. European Journal of Haematology, 2007, 79, 146-149.	2.2	29
192	Zanolimumab (HuMax-CD4 α , ϕ), a Fully Human Monoclonal Antibody: Efficacy and Safety in Patients with Relapsed or Treatment-Refractory Non-Cutaneous CD4+ T-Cell Lymphoma.. Blood, 2007, 110, 3409-3409.	1.4	13
193	Genes and Proteins Associated with the Tumor Microenvironment Are Differentially Expressed in Cured Versus Primary Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma.. Blood, 2007, 110, 3171-3171.	1.4	0
194	Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.. Blood, 2007, 110, LB1-LB1.	1.4	5
195	Zanolimumab, a Fully Human Monoclonal Antibody: Preliminary Results of an Ongoing Clinical Trial in CD4+ Peripheral T-Cell Lymphomas (PTCL).. Blood, 2006, 108, 2723-2723.	1.4	1
196	High expression of cyclin B1 predicts a favorable outcome in patients with follicular lymphoma. Blood, 2005, 105, 2908-2915.	1.4	54
197	Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. Modern Pathology, 2005, 18, 1113-1120.	5.5	185
198	SGN-30 (Anti-CD30 Monoclonal Antibody) Is Active and Well Tolerated in Patients with Refractory or Recurrent Systemic Anaplastic Large Cell Lymphoma (ALCL).. Blood, 2005, 106, 3356-3356.	1.4	1

#	ARTICLE	IF	CITATIONS
199	Nordic Mantle Cell Lymphoma (MCL) Project: Preemptive Rituximab Treatment of Molecular Relapse Following Autotransplant Can Reinduce Molecular Remission and Prolonged Disease-Free Survival.. Blood, 2005, 106, 2429-2429.	1.4	1
200	ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma – the Nordic Lymphoma Group experience. European Journal of Haematology, 2004, 73, 179-182.	2.2	33
201	Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma? a Nordic Lymphoma Group study. Annals of Hematology, 2004, 83, 414-419.	1.8	61
202	Nordic Mantle Cell Lymphoma (MCL) Project: Prolonged Follow-Up of 86 Patients Treated with BEAM/BEAC + PBSCT Confirms That Addition of High-Dose Ara-C and Rituximab to CHOP Induction + In-Vivo Purging with Rituximab Increases Clinical and Molecular Response Rates, PCR-Neg. Grafts, Failure-Free, Relapse-Free and Overall Survival.. Blood, 2004, 104, 8-8.	1.4	4
203	Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood, 2003, 101, 4047-4054.	1.4	99
204	Immunohistochemical expression of CD23 and CD40 may identify prognostically favorable subgroups of diffuse large B-cell lymphoma: a Nordic Lymphoma Group Study. Clinical Cancer Research, 2003, 9, 722-8.	7.0	60
205	Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma - a Nordic Lymphoma Group study. International Journal of Oncology, 2002, 20, 161-5.	3.3	10
206	Health-Related Quality of Life and Its Potential Prognostic Implications in Patients with Aggressive Lymphoma. Medical Oncology, 2001, 18, 85-94.	2.5	41
207	Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. British Journal of Cancer, 2001, 84, 303-307.	6.4	40
208	Residual Mass in Aggressive Lymphoma - Does Size, Measured by Computed Tomography, Influence Clinical Outcome?. Acta Oncologica, 2000, 39, 485-489.	1.8	12
209	CHOP versus MACOP-B in aggressive lymphoma - a Nordic Lymphoma Group randomised trial. Annals of Oncology, 1999, 10, 1079-1086.	1.2	48
210	Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas. European Journal of Haematology, 1999, 62, 184-190.	2.2	21
211	Bacteremic and non-bacteremic febrile urinary tract infection – a review of 168 hospital-treated patients. Infection, 1992, 20, 143-145.	4.7	45